{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:02:46Z","timestamp":1760101366582},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Faculty of Medicine, Khon Kaen University","award":["IN60328"],"award-info":[{"award-number":["IN60328"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Liver disease remains a major critical challenge in Thailand due to viral hepatitis. Clinical management requires close monitoring of liver fibrosis severity. Non-invasive testing is an attractive method for probing of disease progression. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for fibrosis staging. The current study evaluates the marker among healthy donors and hepatitis C (HCV) patients. 100 HCV subjects were evaluated by liver biopsy. These patients had varying fibrosis severity based on METAVIR scores. Healthy donors were confirmed based on normal liver functions tests. Comparisons of M2BPGi levels among different study groups were performed and the effectiveness was evaluated using receiver operating characteristics (ROC) curves. Using liver biopsy as the reference standard, median M2BPGi levels in HCV cases were 0.74, 1.38 and 2.88 COI for F0-1, F2 and\u2009&gt;\u2009F3 cases respectively. In healthy donors, the baseline values ranged 0.1\u20130.24 COI and statistically lower than liver disease cases profiled using M2BPGi. ROC analysis demonstrated superior results for M2BPGi levels among diseased populations and healthy controls. AUROC was determined at 0.983. Comparing with other non-invasive tests, M2BPGi showed a positive linear trend that indicated a strong match to existing methodologies. M2BPGi addresses a critical need in the management of liver disease by providing straightforward means to probe fibrosis severity. In this study, we found significant differences between hepatitis C and healthy subjects and established the background level in healthy donors.<\/jats:p>","DOI":"10.1038\/s41598-022-10744-5","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T10:09:28Z","timestamp":1650967768000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of Mac-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Kawin","family":"Tangvoraphonkchai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanita","family":"Suttichaimongkol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Churairat","family":"Kularbkaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakasit","family":"Sangaimwibool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wattana","family":"Sukeepaisarnjaroen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"10744_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151\u2013171. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014 (2019).","journal-title":"J. Hepatol."},{"key":"10744_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"2018","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 394. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"10744_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","volume":"1","author":"S Wait","year":"2016","unstructured":"Wait, S. et al. Hepatitis B and hepatitis C in southeast and southern Asia: Challenges for governments. Lancet Gastroenterol. Hepatol. 1, 248\u2013255. https:\/\/doi.org\/10.1016\/S2468-1253(16)30031-0 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10744_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/jgh.13385","volume":"31","author":"JC Koh","year":"2016","unstructured":"Koh, J. C. et al. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J. Gastroenterol. Hepatol. 31, 1405\u20131413. https:\/\/doi.org\/10.1111\/jgh.13385 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10744_CR5","doi-asserted-by":"publisher","first-page":"e0196301","DOI":"10.1371\/journal.pone.0196301","volume":"13","author":"R Wasitthankasem","year":"2018","unstructured":"Wasitthankasem, R. et al. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS ONE 13, e0196301. https:\/\/doi.org\/10.1371\/journal.pone.0196301 (2018).","journal-title":"PLoS ONE"},{"key":"10744_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12876-021-01720-w","volume":"21","author":"P Phisalprapa","year":"2021","unstructured":"Phisalprapa, P. et al. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol. 21, 135. https:\/\/doi.org\/10.1186\/s12876-021-01720-w (2021).","journal-title":"BMC Gastroenterol."},{"key":"10744_CR7","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","volume":"97","author":"A Regev","year":"2002","unstructured":"Regev, A. et al. Sampling error and intraobserver variation in liver biopsy in pat. Am. J. Gastroenterol. 97, 2614\u20132618. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.06038.x (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"10744_CR8","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin, L. et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 29, 1705\u20131713. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2003.07.001 (2003).","journal-title":"Ultrasound Med. Biol."},{"key":"10744_CR9","doi-asserted-by":"publisher","first-page":"7169","DOI":"10.12659\/MSM.916533","volume":"25","author":"CC Chen","year":"2019","unstructured":"Chen, C. C. et al. Diagnostic accuracy of acoustic radiation force impulse (ARFI) and Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA(+)-M2BP) in patients with chronic liver disease. Med. Sci. Monit. 25, 7169\u20137174. https:\/\/doi.org\/10.12659\/MSM.916533 (2019).","journal-title":"Med. Sci. Monit."},{"key":"10744_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/jvh.12680","volume":"24","author":"F Yu","year":"2017","unstructured":"Yu, F. et al. Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients. J. Viral Hepat. 24, 580\u2013588. https:\/\/doi.org\/10.1111\/jvh.12680 (2017).","journal-title":"J. Viral Hepat."},{"key":"10744_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/srep01065","volume":"3","author":"A Kuno","year":"2013","unstructured":"Kuno, A. et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 3, 1065. https:\/\/doi.org\/10.1038\/srep01065 (2013).","journal-title":"Sci. Rep."},{"key":"10744_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00535-014-0946-y","volume":"50","author":"T Toshima","year":"2015","unstructured":"Toshima, T. et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 50, 76\u201384. https:\/\/doi.org\/10.1007\/s00535-014-0946-y (2015).","journal-title":"J Gastroenterol."},{"key":"10744_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.954","author":"Y Eso","year":"2021","unstructured":"Eso, Y. et al. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. J. Hepatobil. Pancreat Sci. https:\/\/doi.org\/10.1002\/jhbp.954 (2021).","journal-title":"J. Hepatobil. Pancreat Sci."},{"key":"10744_CR14","doi-asserted-by":"publisher","first-page":"e25110","DOI":"10.1097\/MD.0000000000025110","volume":"100","author":"A Nozaki","year":"2021","unstructured":"Nozaki, A. et al. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study. Medicine 100, e25110. https:\/\/doi.org\/10.1097\/MD.0000000000025110 (2021).","journal-title":"Medicine"},{"key":"10744_CR15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.21037\/atm-20-5216","volume":"8","author":"H Park","year":"2020","unstructured":"Park, H., Jun, D. W., Park, H. K. & Kim, M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann. Transl. Med. 8, 1583. https:\/\/doi.org\/10.21037\/atm-20-5216 (2020).","journal-title":"Ann. Transl. Med."},{"key":"10744_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12072-019-09928-5","volume":"13","author":"LY Mak","year":"2019","unstructured":"Mak, L. Y. et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatol. Int. 13, 148\u2013156. https:\/\/doi.org\/10.1007\/s12072-019-09928-5 (2019).","journal-title":"Hepatol. Int."},{"key":"10744_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00535-020-01715-6","volume":"55","author":"M Nakagawa","year":"2020","unstructured":"Nakagawa, M. et al. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J. Gastroenterol. 55, 990\u2013999. https:\/\/doi.org\/10.1007\/s00535-020-01715-6 (2020).","journal-title":"J. Gastroenterol."},{"key":"10744_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4254\/wjh.v12.i5.220","volume":"12","author":"TTT Pham","year":"2020","unstructured":"Pham, T. T. T., Ho, D. T. & Nguyen, T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J. Hepatol. 12, 220\u2013228. https:\/\/doi.org\/10.4254\/wjh.v12.i5.220 (2020).","journal-title":"World J. Hepatol."},{"key":"10744_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/hepr.13630","volume":"51","author":"N Chuaypen","year":"2021","unstructured":"Chuaypen, N. et al. Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. Hepatol Res. 51, 528\u2013537. https:\/\/doi.org\/10.1111\/hepr.13630 (2021).","journal-title":"Hepatol Res."},{"key":"10744_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12876-020-01459-w","volume":"20","author":"N Ueda","year":"2020","unstructured":"Ueda, N. et al. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. BMC Gastroenterol. 20, 314. https:\/\/doi.org\/10.1186\/s12876-020-01459-w (2020).","journal-title":"BMC Gastroenterol."},{"key":"10744_CR21","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3748\/wjg.v26.i21.2864","volume":"26","author":"SA Saleh","year":"2020","unstructured":"Saleh, S. A., Salama, M. M., Alhusseini, M. M. & Mohamed, G. A. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J. Gastroenterol. 26, 2864\u20132876. https:\/\/doi.org\/10.3748\/wjg.v26.i21.2864 (2020).","journal-title":"World J. Gastroenterol."},{"key":"10744_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12876-017-0618-5","volume":"17","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. Accuracy of M2BPGi, compared with Fibro Scan(R), in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol. 17, 62. https:\/\/doi.org\/10.1186\/s12876-017-0618-5 (2017).","journal-title":"BMC Gastroenterol."},{"key":"10744_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12072-016-9754-1","volume":"10","author":"H Nagata","year":"2016","unstructured":"Nagata, H. et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol. Int. 10, 956\u2013964. https:\/\/doi.org\/10.1007\/s12072-016-9754-1 (2016).","journal-title":"Hepatol. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10744-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10744-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10744-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:07:52Z","timestamp":1669342072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10744-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10744"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10744-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"27 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6757"}}